Neuromuscular Blocking Agents for ARDS: Incentive for Personalized Medicine

References

1. 1.↵
   1. Torbic H,
   2. Krishnan S,
   3. Harnegie MP,
   4. Duggal A

   . Neuromuscular blocking agents for ARDS: a systematic review and meta-analysis. Respir Care 2021;66(1):120–128.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   1. Slutsky AS

   . Neuromuscular blocking agents in ARDS. N Engl J Med 2010;363(12):1176–1180.

   OpenUrlCrossRefPubMedWeb of Science
3. 3.
   1. Gattinoni L,
   2. Marini JJ

   . Prone positioning and neuromuscular blocking agents are part of standard care in severe ARDS patients: we are not sure. Intensive Care Med 2015;41(12):2201–2203.

   OpenUrl
4. 4.↵
   1. Hraiech S,
   2. Forel JM,
   3. Papazian L

   . The role of neuromuscular blockers in ARDS: benefits and risks. Curr Opin Crit Care 2012;18(5):495–502.

   OpenUrlPubMed
5. 5.↵
   1. Thompson BT,
   2. Chambers RC,
   3. Liu KD

   . Acute respiratory distress syndrome. N Engl J Med 2017;377(6):562–572.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Andrade C

   . The use and limitations of the fragility index in the interpretation of clinical trial findings. J Clin Psychiatry 2020;81(2):20f13334.

   OpenUrl
7. 7.↵
   1. Ridgeon EE,
   2. Young PJ,
   3. Bellomo R,
   4. Mucchetti M,
   5. Lembo R,
   6. Landoni G

   . The fragility index in multicenter randomized controlled critical care crials. Crit Care Med 2016;44(7):1278–1284.

   OpenUrlCrossRefPubMed
8. 8.↵
   Cochrane Scientific Committee. Should Cochrane apply error-adjustment methods when conducting repeated meta-analyses? 2018. Available at: https://methods.cochrane.org/sites/default/files/public/uploads/tsa_expert_panel_guidance_and_recommendation_final.pdf. Accessed February 1, 2021.
9. 9.↵
   1. Murray MJ,
   2. DeBlock H,
   3. Erstad B,
   4. Gray A,
   5. Jacobi J,
   6. Jordan C,
   7. et al

   . Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient. Crit Care Med 2016;44(11):2079–2103.

   OpenUrl
10. 10.↵
    1. Papazian L,
    2. Aubron C,
    3. Brochard L,
    4. Chiche JD,
    5. Combes A,
    6. Dreyfuss D,
    7. et al

    . Formal guidelines: management of acute respiratory distress syndrome. Ann Intensive Care 2019;9(1):69.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Calfee CS,
    2. Delucchi K,
    3. Parsons PE,
    4. Thompson BT,
    5. Ware LB,
    6. Matthay MA

    . Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. Lancet Respir Med 2014;2(8):611–620.

    OpenUrl
12. 12.↵
    1. Calfee CS,
    2. Delucchi KL,
    3. Sinha P,
    4. Matthay MA,
    5. Hackett J,
    6. Shankar-Hari M,
    7. et al

    . Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial. Lancet Respir Med 2018;6(9):691–698.

    OpenUrl